Information

Related Research Units

Neurology Research
F.M. Kirby Neurobiology Center

Research Overview

Our laboratory's major focus is on the development of novel methods to treat brain injury, particularly the type of brain injury that leads to epilepsy. We work to identify biological targets which can stop or prevent seizures if manipulated by either brain stimulation or by novel drugs that we are testing in our lab.

We have adapted methods for transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) to rodents, to in vitro brain slice preparations, and more recently to zebrafish (an emerging experimental tool in epilepsy). TMS and tDCS have in common the capacity to safely induce durable changes in neuronal activity. Limited experience with human patients, including those treated at Boston Children's Hospital, shows that TMS and tDCS have realistic prospects in suppressing seizures. Yet whether these techniques can prevent the onset of epilepsy after various forms of brain injury has not been tested. To characterize the cellular mechanisms by which TMS and tDCS exert their effect, and ultimately to optimize their clinical efficacy, we are testing these techniques in rodent epilepsy models, including models of traumatic brain injury (TBI).

To determine how best to match the cellular changes induced by noninvasive brain stimulation those of brain injury and epilepsy, we are also studying the molecular changes associated with TBI in rats. A second major focus has grown out of this work: testing novel pharmaceutical approaches to prevent brain injury and seizures after TBI.

In parallel to our laboratory experiments, we have ongoing clinical projects aimed to further develop techniques for noninvasive brain stimulation, particularly TMS and tDCS, as diagnostic and therapeutic tools in child neurology.

Research Background

Alex Rotenberg was born in Chernovtsy, Ukraine. He is a graduate of Johns Hopkins University (BA) and the State University of New York, Downstate Medical Center (MD, PhD). He is an active member of the American Epilepsy Society. His current appointment is as Associate Professor of Neurology, Harvard Medical School. Dr. Rotenberg is the recipient of the 2016 Dreifuss-Penry Epilepsy Award from the American Academy of Neurology.

Education

Undergraduate School

Johns Hopkins University
1993 Baltimore MD

Medical School

SUNY Health Science Center at Brooklyn
2000 Brooklyn NY

Residency

Pediatrics Mount Sinai School of Medicine
2002 New York NY

Residency

Neurology Boston Children's Hospital
2005 Boston MA

Fellowship

Epilepsy and Clinical Neurophysiology Boston Children's Hospital
2006 Boston MA United States

Publications

  1. Alpha-Delta Ratio for Detection of Cerebral Injury and Stroke in Pediatric Extracorporeal Membrane Oxygenation. J Clin Neurophysiol. 2024 Nov 25. View Abstract
  2. Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept. Ann Neurol. 2025 Feb; 97(2):344-357. View Abstract
  3. The role of parvalbumin interneuron dysfunction across neurodegenerative dementias. Ageing Res Rev. 2024 Nov; 101:102509. View Abstract
  4. A comparison of the antiepileptogenic efficacy of two rationally chosen multitargeted drug combinations in a rat model of posttraumatic epilepsy. Exp Neurol. 2024 Dec; 382:114962. View Abstract
  5. Transient Ipsilateral Hemineglect Following Brain Laser Ablation in Patient with Focal Cortical Dysplasia. Neurol Int. 2024 Sep 03; 16(5):958-965. View Abstract
  6. Case report: Tremor in the placebo condition of a blinded clinical trial of intermittent theta-burst stimulation for cocaine use disorder. Front Psychiatry. 2024; 15:1391771. View Abstract
  7. Zebrafish models of candidate human epilepsy-associated genes provide evidence of hyperexcitability. iScience. 2024 Jul 19; 27(7):110172. View Abstract
  8. Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder. J Neurodev Disord. 2024 Apr 24; 16(1):21. View Abstract
  9. Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2024 05; 47(3):476-493. View Abstract
  10. Consensus guidelines for the diagnosis and management of succinic semialdehyde dehydrogenase deficiency. Mol Genet Metab. 2024 May; 142(1):108363. View Abstract
  11. Zebrafish models of candidate human epilepsy-associated genes provide evidence of hyperexcitability. bioRxiv. 2024 Feb 08. View Abstract
  12. Background EEG Suppression Ratio for Early Detection of Cerebral Injury in Pediatric Cardiac Arrest. Neurocrit Care. 2024 Aug; 41(1):156-164. View Abstract
  13. Glymphatic dysfunction coincides with lower GABA levels and sleep disturbances in succinic semialdehyde dehydrogenase deficiency. J Sleep Res. 2024 Aug; 33(4):e14105. View Abstract
  14. Deep Learning-Based Visual Complexity Analysis of Electroencephalography Time-Frequency Images: Can It Localize the Epileptogenic Zone in the Brain? Algorithms. 2023 Dec; 16(12). View Abstract
  15. Phenotypic correlates of structural and functional protein impairments resultant from ALDH5A1 variants. Hum Genet. 2023 Dec; 142(12):1755-1776. View Abstract
  16. Synaptic BMAL1 phosphorylation controls circadian hippocampal plasticity. Sci Adv. 2023 10 27; 9(43):eadj1010. View Abstract
  17. Prevalence of suicidality in children and adolescents with depressive disorders with and without epilepsy. Epilepsy Behav. 2023 Nov; 148:109467. View Abstract
  18. Shortened Motor Evoked Potential Latency in the Epileptic Hemisphere of Children With Focal Epilepsy. J Clin Neurophysiol. 2024 Sep 01; 41(6):530-536. View Abstract
  19. Sleep Spindle Generation Before and After Epilepsy Surgery: A Source Imaging Study in Children with Drug-Resistant Epilepsy. Brain Topogr. 2024 01; 37(1):88-101. View Abstract
  20. Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor. Ann Clin Transl Neurol. 2023 10; 10(10):1790-1801. View Abstract
  21. Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS). J Neurodev Disord. 2023 07 26; 15(1):22. View Abstract
  22. Depressed glutamate transporter 1 expression in a mouse model of Dravet syndrome. Ann Clin Transl Neurol. 2023 09; 10(9):1695-1699. View Abstract
  23. Phenotypic Correlates of Structural and Functional Protein Impairments Resultant from ALDH5A1 Variants. Res Sq. 2023 Jul 10. View Abstract
  24. Autism spectrum disorder and GABA levels in children with succinic semialdehyde dehydrogenase deficiency. Dev Med Child Neurol. 2023 12; 65(12):1596-1606. View Abstract
  25. The presence and severity of epilepsy coincide with reduced ?-aminobutyrate and cortical excitatory markers in succinic semialdehyde dehydrogenase deficiency. Epilepsia. 2023 06; 64(6):1516-1526. View Abstract
  26. N-acetylcysteine treatment mitigates loss of cortical parvalbumin-positive interneuron and perineuronal net integrity resulting from persistent oxidative stress in a rat TBI model. Cereb Cortex. 2023 03 21; 33(7):4070-4084. View Abstract
  27. New Therapeutic Approaches to Inherited Metabolic Pediatric Epilepsies. Neurology. 2023 07 18; 101(3):124-133. View Abstract
  28. Preclinical pharmacokinetics and tolerability of a novel meglumine-based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia. 2023 04; 64(4):888-899. View Abstract
  29. Systemic inflammation as a biomarker of seizure propensity and a target for treatment to reduce seizure propensity. Epilepsia Open. 2023 03; 8(1):221-234. View Abstract
  30. Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation. Neuropsychopharmacology. 2023 01; 48(1):191-208. View Abstract
  31. Interictal Connectivity Revealed by Granger Analysis of Stereoelectroencephalography: Association With Ictal Onset Zone, Resection, and Outcome. Neurosurgery. 2022 10 01; 91(4):583-589. View Abstract
  32. Discrepant expressive language lateralization in children and adolescents with epilepsy. Ann Clin Transl Neurol. 2022 09; 9(9):1459-1464. View Abstract
  33. Identifying biomarkers for epilepsy after cerebral malaria in Zambian children: rationale and design of a prospective observational study. BMJ Open. 2022 07 18; 12(7):e062948. View Abstract
  34. Language Mapping using tEEG and EEG Data with Convolutional Neural Networks. Annu Int Conf IEEE Eng Med Biol Soc. 2022 07; 2022:4060-4063. View Abstract
  35. Preliminary Report of the Safety and Tolerability of 1 Hz Repetitive Transcranial Magnetic Stimulation in Temporal Lobe Epilepsy. J Cent Nerv Syst Dis. 2022; 14:11795735221088522. View Abstract
  36. Single-stage resection of bottom-of-a-sulcus dysplasia involving eloquent cortex using navigated transcranial magnetic stimulation and intraoperative modalities. Childs Nerv Syst. 2022 07; 38(7):1365-1370. View Abstract
  37. Mosaic and non-mosaic protocadherin 19 mutation leads to neuronal hyperexcitability in zebrafish. Neurobiol Dis. 2022 07; 169:105738. View Abstract
  38. Automated detection of absence seizures using a wearable electroencephalographic device: a phase 3 validation study and feasibility of automated behavioral testing. Epilepsia. 2023 Dec; 64 Suppl 4:S40-S46. View Abstract
  39. Understanding the Molecular Mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): Towards the Development of SSADH-Targeted Medicine. Int J Mol Sci. 2022 Feb 26; 23(5). View Abstract
  40. Biomarkers Obtained by Transcranial Magnetic Stimulation in Neurodevelopmental Disorders. J Clin Neurophysiol. 2022 Feb 01; 39(2):135-148. View Abstract
  41. Neuronal Loss of the Glutamate Transporter GLT-1 Promotes Excitotoxic Injury in the Hippocampus. Front Cell Neurosci. 2021; 15:788262. View Abstract
  42. Early Repetitive Transcranial Magnetic Stimulation Exerts Neuroprotective Effects and Improves Motor Functions in Hemiparkinsonian Rats. Neural Plast. 2021; 2021:1763533. View Abstract
  43. Quantitative Electroencephalography for Early Detection of Elevated Intracranial Pressure in Critically Ill Children: Case Series and Proposed Protocol. J Child Neurol. 2022 01; 37(1):5-11. View Abstract
  44. A "Proof of Concept" Randomized Controlled Trial of a Video Game Requiring Emotional Regulation to Augment Anger Control Training. Front Psychiatry. 2021; 12:591906. View Abstract
  45. Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities. Nat Rev Drug Discov. 2021 09; 20(9):653-654. View Abstract
  46. Clinical Characterization of Epilepsy in Children With Angelman Syndrome. Pediatr Neurol. 2021 11; 124:42-50. View Abstract
  47. Personalised, image-guided, noninvasive brain stimulation in gliomas: Rationale, challenges and opportunities. EBioMedicine. 2021 Aug; 70:103514. View Abstract
  48. Factors influencing the acute pentylenetetrazole-induced seizure paradigm and a literature review. Ann Clin Transl Neurol. 2021 07; 8(7):1388-1397. View Abstract
  49. Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice. Sci Transl Med. 2021 06 02; 13(596). View Abstract
  50. Transcranial Magnetic Stimulation in Succinic Semialdehyde Dehydrogenase Deficiency: A Measure of Maturational Trajectory of Cortical Excitability. J Child Neurol. 2021 11; 36(13-14):1169-1176. View Abstract
  51. Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation. Transl Psychiatry. 2021 05 27; 11(1):325. View Abstract
  52. Personalized, Multisession, Multichannel Transcranial Direct Current Stimulation in Medication-Refractory Focal Epilepsy: An Open-Label Study. J Clin Neurophysiol. 2023 Jan 01; 40(1):53-62. View Abstract
  53. Modulation of motor cortical excitability by continuous theta-burst stimulation in adults with autism spectrum disorder. Clin Neurophysiol. 2021 07; 132(7):1647-1662. View Abstract
  54. Enzyme Replacement Therapy for Succinic Semialdehyde Dehydrogenase Deficiency: Relevance in ?-Aminobutyric Acid Plasticity. J Child Neurol. 2021 11; 36(13-14):1200-1209. View Abstract
  55. A pathogenic UFSP2 variant in an autosomal recessive form of pediatric neurodevelopmental anomalies and epilepsy. Genet Med. 2021 05; 23(5):900-908. View Abstract
  56. In-session seizures during transcranial direct current stimulation in patients with epilepsy. Brain Stimul. 2021 Jan-Feb; 14(1):152-153. View Abstract
  57. EEG markers predictive of epilepsy risk in pediatric cerebral malaria - A feasibility study. Epilepsy Behav. 2020 12; 113:107536. View Abstract
  58. Increase in Seizure Susceptibility After Repetitive Concussion Results from Oxidative Stress, Parvalbumin-Positive Interneuron Dysfunction and Biphasic Increases in Glutamate/GABA Ratio. Cereb Cortex. 2020 11 03; 30(12):6108-6120. View Abstract
  59. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 01; 132(1):269-306. View Abstract
  60. Drug-Responsive Inhomogeneous Cortical Modulation by Direct Current Stimulation. Ann Neurol. 2020 09; 88(3):489-502. View Abstract
  61. Review of Transcranial Magnetic Stimulation in Epilepsy. Clin Ther. 2020 07; 42(7):1155-1168. View Abstract
  62. Targeting Gamma-Related Pathophysiology in Autism Spectrum Disorder Using Transcranial Electrical Stimulation: Opportunities and Challenges. Autism Res. 2020 07; 13(7):1051-1071. View Abstract
  63. Localized Disruption of Blood Albumin-Phenytoin Binding Using Transcranial Focused Ultrasound. Ultrasound Med Biol. 2020 08; 46(8):1986-1997. View Abstract
  64. Continuous Theta-Burst Stimulation in Children With High-Functioning Autism Spectrum Disorder and Typically Developing Children. Front Integr Neurosci. 2020; 14:13. View Abstract
  65. Emerging Applications of Noninvasive Brain Stimulation. J Clin Neurophysiol. 2020 03; 37(2):89. View Abstract
  66. Noninvasive Brain Stimulation in Epilepsy. J Clin Neurophysiol. 2020 Mar; 37(2):118-130. View Abstract
  67. Safety and Tolerability of Repetitive Transcranial Magnetic Stimulation During Pregnancy: A Case Report and Literature Review. J Clin Neurophysiol. 2020 Mar; 37(2):164-169. View Abstract
  68. Cortical Excitability, Synaptic Plasticity, and Cognition in Benign Epilepsy With Centrotemporal Spikes: A Pilot TMS-EMG-EEG Study. J Clin Neurophysiol. 2020 Mar; 37(2):170-180. View Abstract
  69. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia. 2020 03; 61(3):359-386. View Abstract
  70. Transcranial magnetic stimulation tracks subminute changes in cortical excitability during propofol anesthesia. Ann Clin Transl Neurol. 2020 03; 7(3):384-389. View Abstract
  71. Early transcranial direct current stimulation treatment exerts neuroprotective effects on 6-OHDA-induced Parkinsonism in rats. Brain Stimul. 2020 May - Jun; 13(3):655-663. View Abstract
  72. Patterns of anti-seizure medication (ASM) use in pediatric patients with surgically managed epilepsy: A retrospective review of data from Boston Children's Hospital. Epilepsy Res. 2020 02; 160:106257. View Abstract
  73. Safety of rTMS in patients with intracranial metallic objects. Brain Stimul. 2020 May - Jun; 13(3):928-929. View Abstract
  74. Neuromodulatory Effects of Transcranial Direct Current Stimulation on Motor Excitability in Rats. Neural Plast. 2019; 2019:4252943. View Abstract
  75. Ceftriaxone Treatment Preserves Cortical Inhibitory Interneuron Function via Transient Salvage of GLT-1 in a Rat Traumatic Brain Injury Model. Cereb Cortex. 2019 12 17; 29(11):4506-4518. View Abstract
  76. Biomarkers Obtained by Transcranial Magnetic Stimulation of the Motor Cortex in Epilepsy. Front Integr Neurosci. 2019; 13:57. View Abstract
  77. Regulation of lifespan by neural excitation and REST. Nature. 2019 10; 574(7778):359-364. View Abstract
  78. Maturation of Corticospinal Tracts in Children With Hemiplegic Cerebral Palsy Assessed by Diffusion Tensor Imaging and Transcranial Magnetic Stimulation. Front Hum Neurosci. 2019; 13:254. View Abstract
  79. Test-Retest Reliability of the Effects of Continuous Theta-Burst Stimulation. Front Neurosci. 2019; 13:447. View Abstract
  80. Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism. Ann Neurol. 2019 06; 85(6):921-926. View Abstract
  81. De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias. Am J Hum Genet. 2019 Mar 07; 104(3):562. View Abstract
  82. Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes. Biol Psychiatry. 2019 05 01; 85(9):752-759. View Abstract
  83. Electrographic spikes are common in wildtype mice. Epilepsy Behav. 2018 12; 89:94-98. View Abstract
  84. De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias. Am J Hum Genet. 2018 11 01; 103(5):666-678. View Abstract
  85. Dietary, immunological, surgical, and other emerging treatments for pediatric refractory status epilepticus. Seizure. 2019 May; 68:89-96. View Abstract
  86. Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzyme-replacement therapeutic strategies. J Inherit Metab Dis. 2018 07; 41(4):699-708. View Abstract
  87. A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. Neurobiol Dis. 2018 03; 111:91-101. View Abstract
  88. The Need for Antiepileptic Drug Chronotherapy to Treat Selected Childhood Epilepsy Syndromes and Avert the Harmful Consequences of Drug Resistance. J Cent Nerv Syst Dis. 2017; 9:1179573516685883. View Abstract
  89. mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. Neuropsychopharmacology. 2018 05; 43(6):1457-1465. View Abstract
  90. Trajectory of Parvalbumin Cell Impairment and Loss of Cortical Inhibition in Traumatic Brain Injury. Cereb Cortex. 2017 12 01; 27(12):5509-5524. View Abstract
  91. Alterations in the Timing of Huperzine A Cerebral Pharmacodynamics in the Acute Traumatic Brain Injury Setting. J Neurotrauma. 2018 01 15; 35(2):393-397. View Abstract
  92. A randomized controlled trial of levodopa in patients with Angelman syndrome. Am J Med Genet A. 2018 05; 176(5):1099-1107. View Abstract
  93. Interindividual variability in response to continuous theta-burst stimulation in healthy adults. Clin Neurophysiol. 2017 11; 128(11):2268-2278. View Abstract
  94. Persistent uncrossed corticospinal connections in patients with intractable focal epilepsy. Epilepsy Behav. 2017 10; 75:66-71. View Abstract
  95. Correction: Relationship of mechanical impact magnitude to neurologic dysfunction severity in a rat traumatic brain injury model. PLoS One. 2017; 12(7):e0182300. View Abstract
  96. Response to letter to the editor: Safety of transcranial direct current stimulation: Evidence based update 2016. Brain Stimul. 2017 Sep - Oct; 10(5):986-987. View Abstract
  97. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism. Mol Autism. 2017; 8:26. View Abstract
  98. Relationship of mechanical impact magnitude to neurologic dysfunction severity in a rat traumatic brain injury model. PLoS One. 2017; 12(5):e0178186. View Abstract
  99. Memantine improves outcomes after repetitive traumatic brain injury. Behav Brain Res. 2018 03 15; 340:195-204. View Abstract
  100. Surface EEG-Transcranial Direct Current Stimulation (tDCS) Closed-Loop System. Int J Neural Syst. 2017 Sep; 27(6):1750026. View Abstract
  101. The Number of Pulses Needed to Measure Corticospinal Excitability by Navigated Transcranial Magnetic Stimulation: Eyes Open vs. Close Condition. Front Hum Neurosci. 2017; 11:121. View Abstract
  102. Transcranial Magnetic and Direct Current Stimulation in Children. Curr Neurol Neurosci Rep. 2017 02; 17(2):11. View Abstract
  103. Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease. Med Hypotheses. 2017 Feb; 99:57-62. View Abstract
  104. Neurophysiological evidence of preserved connectivity in tuber tissue. Epilepsy Behav Case Rep. 2017; 7:64-68. View Abstract
  105. Characterizing and Modulating Brain Circuitry through Transcranial Magnetic Stimulation Combined with Electroencephalography. Front Neural Circuits. 2016; 10:73. View Abstract
  106. Pediatric Neuromodulation Comes of Age. J Child Adolesc Psychopharmacol. 2016 09; 26(7):578-81. View Abstract
  107. Bursts of high-frequency repetitive transcranial magnetic stimulation (rTMS), together with lorazepam, suppress seizures in a rat kainate status epilepticus model. Epilepsy Behav. 2016 09; 62:136-9. View Abstract
  108. Correction: Microarray Noninvasive Neuronal Seizure Recordings from Intact Larval Zebrafish. PLoS One. 2016; 11(7):e0159472. View Abstract
  109. Direct current stimulation induces mGluR5-dependent neocortical plasticity. Ann Neurol. 2016 08; 80(2):233-46. View Abstract
  110. Construction and Evaluation of Rodent-Specific rTMS Coils. Front Neural Circuits. 2016; 10:47. View Abstract
  111. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct; 9(5):641-661. View Abstract
  112. Microarray Noninvasive Neuronal Seizure Recordings from Intact Larval Zebrafish. PLoS One. 2016; 11(6):e0156498. View Abstract
  113. Abnormal Mechanisms of Plasticity and Metaplasticity in Autism Spectrum Disorders and Fragile X Syndrome. J Child Adolesc Psychopharmacol. 2016 09; 26(7):617-24. View Abstract
  114. Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research. Expert Rev Neurother. 2016 06; 16(6):671-80. View Abstract
  115. H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report. Epilepsy Behav Case Rep. 2016; 5:52-6. View Abstract
  116. Safety of repetitive transcranial magnetic stimulation in patients with epilepsy: A systematic review. Epilepsy Behav. 2016 Apr; 57(Pt A):167-176. View Abstract
  117. N100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth. Neural Plast. 2016; 2016:4209831. View Abstract
  118. Noninvasive Brain Stimulation in Pediatric Attention-Deficit Hyperactivity Disorder (ADHD): A Review. J Child Neurol. 2016 May; 31(6):784-96. View Abstract
  119. Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. Schizophr Res. 2015 Dec; 169(1-3):340-345. View Abstract
  120. Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research. Autism Res. 2016 Feb; 9(2):184-203. View Abstract
  121. Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker. BMC Med. 2015 Nov 02; 13:276. View Abstract
  122. Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition. Epilepsy Res. 2015 Nov; 117:97-103. View Abstract
  123. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015 Jul 23; 523(7561):431-436. View Abstract
  124. Acute seizure suppression by transcranial direct current stimulation in rats. Ann Clin Transl Neurol. 2015 Aug; 2(8):843-56. View Abstract
  125. Commentary on IL-1ß associations with posttraumatic epilepsy development: A genetics and biomarker cohort study. Epilepsia. 2015 Jul; 56(7):989-90. View Abstract
  126. Glutamate and GABA imbalance following traumatic brain injury. Curr Neurol Neurosci Rep. 2015 May; 15(5):27. View Abstract
  127. Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression. Proc Natl Acad Sci U S A. 2015 Apr 21; 112(16):5129-34. View Abstract
  128. Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J Neurosci. 2015 Apr 01; 35(13):5187-201. View Abstract
  129. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb; 45(2):524-36. View Abstract
  130. Transcranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014. Front Hum Neurosci. 2014; 8:1034. View Abstract
  131. 15years of welcome contribution to epilepsy research. Epilepsy Behav. 2014 Nov; 40:127. View Abstract
  132. Passive fMRI mapping of language function for pediatric epilepsy surgical planning: validation using Wada, ECS, and FMAER. Epilepsy Res. 2014 Dec; 108(10):1874-88. View Abstract
  133. Hippocampal immediate early gene transcription in the rat fluid percussion traumatic brain injury model. Neuroreport. 2014 Aug 20; 25(12):954-9. View Abstract
  134. Modulation of corticospinal excitability by transcranial magnetic stimulation in children and adolescents with autism spectrum disorder. Front Hum Neurosci. 2014; 8:627. View Abstract
  135. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014 Aug; 55(8):1235-44. View Abstract
  136. EEG abnormalities and seizures in genetically diagnosed Fragile X syndrome. Int J Dev Neurosci. 2014 Nov; 38:155-60. View Abstract
  137. Comparison of pediatric patients with status epilepticus lasting 5-29 min versus =30 min. Epilepsy Behav. 2014 Aug; 37:1-6. View Abstract
  138. Comparison of risk factors for pediatric convulsive status epilepticus when defined as seizures = 5 min versus seizures = 30 min. Seizure. 2014 Oct; 23(9):692-8. View Abstract
  139. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol. 2014 May 15; 14:70. View Abstract
  140. A rapid lateral fluid percussion injury rodent model of traumatic brain injury and post-traumatic epilepsy. Neuroreport. 2014 May 07; 25(7):532-6. View Abstract
  141. Suppression of motor cortical excitability in anesthetized rats by low frequency repetitive transcranial magnetic stimulation. PLoS One. 2014; 9(3):e91065. View Abstract
  142. Rasmussen's encephalitis presenting as focal cortical dysplasia. Epilepsy Behav Case Rep. 2014; 2:86-9. View Abstract
  143. A measure of acoustic noise generated from transcranial magnetic stimulation coils. Brain Stimul. 2014 May-Jun; 7(3):432-4. View Abstract
  144. Functional Dopaminergic Neurons in Substantia Nigra are Required for Transcranial Magnetic Stimulation-Induced Motor Plasticity. Cereb Cortex. 2015 Jul; 25(7):1806-14. View Abstract
  145. Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol. 2014 Jul; 51(1):60-6. View Abstract
  146. Outcomes of vagal nerve stimulation in a pediatric population: a single center experience. Seizure. 2014 Feb; 23(2):105-11. View Abstract
  147. Long-term response to high-dose diazepam treatment in continuous spikes and waves during sleep. Pediatr Neurol. 2013 Sep; 49(3):163-170.e4. View Abstract
  148. Continuous Spikes and Waves during Sleep: Electroclinical Presentation and Suggestions for Management. Epilepsy Res Treat. 2013; 2013:583531. View Abstract
  149. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma. 2013 Aug 15; 30(16):1434-41. View Abstract
  150. Transcranial magnetic stimulation for refractory focal status epilepticus in the intensive care unit. Seizure. 2013 Dec; 22(10):893-6. View Abstract
  151. Electroencephalography in the pediatric emergency department: when is it most useful? J Child Neurol. 2014 Apr; 29(4):475-82. View Abstract
  152. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One. 2013; 8(3):e57148. View Abstract
  153. Transcranial direct current stimulation for treatment of refractory childhood focal epilepsy. Brain Stimul. 2013 Jul; 6(4):696-700. View Abstract
  154. "RAGE-Control": A Game to Build Emotional Strength. Games Health J. 2013 Feb; 2(1):53-7. View Abstract
  155. The frequency modulated auditory evoked response (FMAER), a technical advance for study of childhood language disorders: cortical source localization and selected case studies. BMC Neurol. 2013 Jan 25; 13:12. View Abstract
  156. Automated quantification of spikes. Epilepsy Behav. 2013 Feb; 26(2):143-52. View Abstract
  157. Epilepsy. Handb Clin Neurol. 2013; 116:491-7. View Abstract
  158. Migraine prophylaxis by anodal transcranial direct current stimulation, a randomized, placebo-controlled trial. J Med Assoc Thai. 2012 Aug; 95(8):1003-12. View Abstract
  159. Translational neuromodulation: approximating human transcranial magnetic stimulation protocols in rats. Neuromodulation. 2012 Jul; 15(4):296-305. View Abstract
  160. Circadian patterns of generalized tonic-clonic evolutions in pediatric epilepsy patients. Seizure. 2012 Sep; 21(7):535-9. View Abstract
  161. Clinical staging and electroencephalographic evolution of continuous spikes and waves during sleep. Epilepsia. 2012 Jul; 53(7):1185-95. View Abstract
  162. Short-term response of sleep-potentiated spiking to high-dose diazepam in electric status epilepticus during sleep. Pediatr Neurol. 2012 May; 46(5):312-8. View Abstract
  163. Early thalamic lesions in patients with sleep-potentiated epileptiform activity. Neurology. 2012 May 29; 78(22):1721-7. View Abstract
  164. Patients with electrical status epilepticus in sleep share similar clinical features regardless of their focal or generalized sleep potentiation of epileptiform activity. J Child Neurol. 2013 Jan; 28(1):83-9. View Abstract
  165. Reply to letter to the editor. Brain Stimul. 2013 Jan; 6(1):95. View Abstract
  166. Contribution of axonal orientation to pathway-dependent modulation of excitatory transmission by direct current stimulation in isolated rat hippocampus. J Neurophysiol. 2012 Apr; 107(7):1881-9. View Abstract
  167. Transcranial magnetic stimulation induces current pulses in transcranial direct current stimulation electrodes. Annu Int Conf IEEE Eng Med Biol Soc. 2012; 2012:811-4. View Abstract
  168. Minimal heating of aneurysm clips during repetitive transcranial magnetic stimulation. Clin Neurophysiol. 2012 Jul; 123(7):1471-3. View Abstract
  169. A new measure of cortical inhibition by mechanomyography and paired-pulse transcranial magnetic stimulation in unanesthetized rats. J Neurophysiol. 2012 Feb; 107(3):966-72. View Abstract
  170. [The use of noninvasive brain stimulation in childhood psychiatric disorders: new diagnostic and therapeutic opportunities and challenges]. Rev Neurol. 2011 Aug 16; 53(4):209-25. View Abstract
  171. Characterizing brain cortical plasticity and network dynamics across the age-span in health and disease with TMS-EEG and TMS-fMRI. Brain Topogr. 2011 Oct; 24(3-4):302-15. View Abstract
  172. Safety and tolerability of repetitive transcranial magnetic stimulation in patients with pathologic positive sensory phenomena: a review of literature. Brain Stimul. 2012 Jul; 5(3):320-329.e27. View Abstract
  173. Commentary on Kratz et Al "seizure in a nonpredisposed individual induced by single-pulse transcranial magnetic stimulation". J ECT. 2011 Jun; 27(2):176-7. View Abstract
  174. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol. 2011 Jun; 44(6):414-9. View Abstract
  175. Teaching Video NeuroImages: complex partial seizure evolving into a psychogenic nonepileptic seizure. Neurology. 2011 May 10; 76(19):1681; author reply 1681. View Abstract
  176. Transcranial brain stimulation: clinical applications and future directions. Neurosurg Clin N Am. 2011 Apr; 22(2):233-51, ix. View Abstract
  177. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. 2012 Jul; 5(3):175-195. View Abstract
  178. Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures. Epilepsia. 2011 Apr; 52(4):753-65. View Abstract
  179. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011 Feb; 20(2):344-8. View Abstract
  180. An estimate of placebo effect of repetitive transcranial magnetic stimulation in epilepsy. Epilepsy Behav. 2011 Feb; 20(2):355-9. View Abstract
  181. Measures of cortical inhibition by paired-pulse transcranial magnetic stimulation in anesthetized rats. J Neurophysiol. 2011 Feb; 105(2):615-24. View Abstract
  182. Teaching Video NeuroImages: complex partial seizure evolving into a psychogenic nonepileptic seizure. Neurology. 2010 Dec 14; 75(24):e98. View Abstract
  183. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol. 2010 Sep; 43(3):155-8. View Abstract
  184. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. Front Synaptic Neurosci. 2010; 2:26. View Abstract
  185. Trisomy 8 mosaicism and favorable outcome after treatment of infantile spasms: case report. J Child Neurol. 2010 Oct; 25(10):1275-7. View Abstract
  186. High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia. 2010 Jul; 51(7):1319-22. View Abstract
  187. Prospects for clinical applications of transcranial magnetic stimulation and real-time EEG in epilepsy. Brain Topogr. 2010 Jan; 22(4):257-66. View Abstract
  188. Lateralization of forelimb motor evoked potentials by transcranial magnetic stimulation in rats. Clin Neurophysiol. 2010 Jan; 121(1):104-8. View Abstract
  189. In-session seizures during low-frequency repetitive transcranial magnetic stimulation in patients with epilepsy. Epilepsy Behav. 2009 Oct; 16(2):353-5. View Abstract
  190. Safety of 1 Hz repetitive transcranial magnetic stimulation (rTMS) in patients with titanium skull plates. Clin Neurophysiol. 2009 Jul; 120(7):1417. View Abstract
  191. Seizure suppression by EEG-guided repetitive transcranial magnetic stimulation in the rat. Clin Neurophysiol. 2008 Dec; 119(12):2697-702. View Abstract
  192. Repetitive transcranial magnetic stimulation in the treatment of epilepsia partialis continua. Epilepsy Behav. 2009 Jan; 14(1):253-7. View Abstract
  193. Transient suppression of seizures by repetitive transcranial magnetic stimulation in a case of Rasmussen's encephalitis. Epilepsy Behav. 2008 Jul; 13(1):260-2. View Abstract
  194. Transcranial magnetic stimulation in child neurology: current and future directions. J Child Neurol. 2008 Jan; 23(1):79-96. View Abstract
  195. Minimal heating of titanium skull plates during 1Hz repetitive transcranial magnetic stimulation. Clin Neurophysiol. 2007 Nov; 118(11):2536-8. View Abstract
  196. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007 May 23; 27(21):5546-58. View Abstract
  197. Safety and tolerability of repetitive transcranial magnetic stimulation in patients with epilepsy: a review of the literature. Epilepsy Behav. 2007 Jun; 10(4):521-8. View Abstract
  198. Electroencephalographic recording during transcranial magnetic stimulation in humans and animals. Clin Neurophysiol. 2006 Aug; 117(8):1870-5. View Abstract
  199. Seizure-induced changes in place cell physiology: relationship to spatial memory. J Neurosci. 2003 Dec 17; 23(37):11505-15. View Abstract
  200. Parallel instabilities of long-term potentiation, place cells, and learning caused by decreased protein kinase A activity. J Neurosci. 2000 Nov 01; 20(21):8096-102. View Abstract
  201. Variable place-cell coupling to a continuously viewed stimulus: evidence that the hippocampus acts as a perceptual system. Philos Trans R Soc Lond B Biol Sci. 1997 Oct 29; 352(1360):1505-13. View Abstract
  202. Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus. Cell. 1996 Dec 27; 87(7):1351-61. View Abstract

Contact Alexander Rotenberg

Print Profile